{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-050058","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.046110+00:00","generated_at":"2026-06-09T05:33:10.111600+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bob Moccia steps down as CEO; Dolev Rafaeli appointed President & CEO; reverse split approved","bullets":["Bob Moccia resigned as CEO and board member effective Oct 30, 2023; receives 9 months base salary severance, no 2023 bonus.","Dr. Dolev Rafaeli appointed Vice-Chairman, President, and CEO; 3-year term, base salary $500k, 75% bonus target, option for 1,745,569 shares.","Shareholders approved reverse stock split of common stock at ratio between 1:5 and 1:25, board to set exact ratio within 6 months.","CFO Chris Lesovitz receives $142,500 retention bonus for staying through filing of FY2023 10-K.","All five director nominees elected; advisory votes on executive compensation and frequency (3 years favored) approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-050058","json":"https://secwatch.observer/filing/0001140361-23-050058.json","markdown":"https://secwatch.observer/filing/0001140361-23-050058.md","text":"https://secwatch.observer/filing/0001140361-23-050058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/ef20013534_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:33:10.111600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2f3373879","claim":"Robert Moccia resigned as Member of the Board of Directors at STRATA Skin Sciences, Inc..","evidence_excerpt":"Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"ef4e30f5f4","claim":"Robert Moccia resigned as Chief Executive Officer and President at STRATA Skin Sciences, Inc..","evidence_excerpt":"Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"fabec7c6b5","claim":"Dolev Rafaeli was appointed as Vice-Chairman of the Board, President and Chief Executive Officer at STRATA Skin Sciences, Inc..","evidence_excerpt":"the Company appointed Dr. Dolev Rafaeli, PhD, (“Rafaeli”), as its Vice-Chairman of the Board, President and Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice-Chairman of the Board, President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"3dc425c7a5467a7855c5ac374a28fbbd37a1edf1","claim":"STRATA Skin Sciences, Inc. shareholders approved Advisory vote to approve compensation of the named executive officers at the 2023-10-26 meeting.","evidence_excerpt":"The advisory vote to approve the compensation of the Company’s named executive officers was approved. Votes For Votes Against Abstain Broker Non-Vote 24,094,572 1,372,175 22,842 4,225,530","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-26"}],"fact_type":"shareholder_vote"},{"claim_id":"4d510d0aeaf814c407de148762492f878e52e95c","claim":"STRATA Skin Sciences, Inc. shareholders approved Advisory vote on the frequency of future advisory votes to approve compensation of named executive officers at the 2023-10-26 meeting.","evidence_excerpt":"The advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers was approved. One Year Two Years Three Years Abstain 11,807,110 55,248 13,612,361 14,886","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-26"}],"fact_type":"shareholder_vote"},{"claim_id":"621b361ea2f2b804ee42da5aa25b0b833dbe8656","claim":"STRATA Skin Sciences, Inc. shareholders approved Election of the five director nominees named in the proxy statement at the 2023-10-26 meeting.","evidence_excerpt":"each of the director’s nominees to the Company’s board of directors was elected: Nominees Votes For Votes Withheld Broker Non-Vote Uri Geiger 24,964,683 524,910 4,225,530 Irit Yaniv 24,962,618 526,987 4,225,530 Wayne Cafran 25,157,665 331,940 4,225,530 Shmuel Rubinstein 24,969,443 520,150 4,225,530 Robert Moccia 23,978264 1,511,341 4,225,530","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-26"}],"fact_type":"shareholder_vote"},{"claim_id":"d9820696cd096fd58cb73251257895252a4d24d3","claim":"STRATA Skin Sciences, Inc. shareholders approved Ratification of the selection of Marcum, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-10-26 meeting.","evidence_excerpt":"Ratification of the selection by the Audit Committee or the Board of Directors of Marcum, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved. Votes For Votes Against Abstain Broker Non-Vote 29,594,033 104,833 16,269 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-26"}],"fact_type":"shareholder_vote"},{"claim_id":"f0d687f52e42431e2f71970cf2ecb50ec790b875","claim":"STRATA Skin Sciences, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split of common stock at a ratio not less than 1-for-5 and no greater than 1-for-25 at the 2023-10-26 meeting.","evidence_excerpt":"The amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of its common stock at a reverse stock split ratio not less than 1-for-5, and no greater than 1-for-25 with the exact split ratio, it approved and effected at all, to be set within that range at the discretion of the Board and publicly announced by the Company within 6 months after stockholder approval at the Annual Meeting without further approval or authorization of the Company’s Stockholders was approved. Votes For Votes Against Abstain Broker Non-Vote 29,015,257 643,214 56,652 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123050058/0001140361-23-050058-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-26"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}